Advertisement

Excitatory dicarboxylic amino acid and pyramidal neurone neurotransmission of the cerebral cortex in Alzheimer’s disease

  • D. M. Bowen
  • S. L. Lowe
Part of the Key Topics in Brain Research book series (KEYTOPICS)

Summary

Drug development for Alzheimer’s disease has so far had little success, possibly due to failure to correct abnormalities of neurones other than the corticopetal. Most enquiries indicate that cortical inhibitory neurotransmitters are neither selectively nor critically affected. It is highly probable that shrinkage or loss of corticocortical association fibres occurs. This change appears to be circumscribed, clinically relevant and to involve neurotransmitter glutamate. Modulatory domains of the N-methyl-D-aspartate receptor complex are identified as sites at which potential therapeutic agents might be safely directed.

Keywords

Pyramidal Neurone Gaba Content Cortical Pyramidal Neurone Glutamic Acid Decarboxylase Activity Primary Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akiyama H, McGeer PL, Itagaki S, McGeer EG, Kaneko T (1989) Loss of glutaminase-positive cortical neurones in Alzheimer’s disease. Neurochem Res 14: 353–358PubMedCrossRefGoogle Scholar
  2. Bowen DM, Allen SJ, Benton JS, Goodhardt MJ, Haan EA, Palmer AM, Sims NR, Smith CCT, Spillane JA, Esiri MM, Snowden JS, Wilcock GK, Davison AN (1983) Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J Neurochem 41: 266–272PubMedCrossRefGoogle Scholar
  3. Carter C, Rivy JP, Scatton B (1989) Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-D-aspartate ( NMDA) receptor. Eur J Pharmacol 164: 611–612PubMedCrossRefGoogle Scholar
  4. Corsellis JAN (1962) Mental illness and the ageing brain, Maudsley Monograph 9. Oxford University Press, LondonGoogle Scholar
  5. Corsellis JAN (1979) Alzheimer’s disease: early recognition of potentially reversible deficits. In: Glen AIM, Whalley LD (eds) Alzheimer’s disease. Early recognition of potentially reversible deficits. Churchill Livingstone, Edinburgh, pp 6Google Scholar
  6. Ellison DW, Beal MF, Mazurek MF, Bird ED, Martin JB (1986) A postmortem study of amino acid neurotransmitters in Alzheimer’s disease. Ann Neurol 20: 616–621PubMedCrossRefGoogle Scholar
  7. Francis PT, Pearson RCA, Lowe SL, Neal JN, Stephens PH, Powell TPS, Bowen DM (1987) The dementia of Alzheimer’s: an update. J Neurol Neurosurg Psychiatry 50: 242–243PubMedCrossRefGoogle Scholar
  8. Hyman BT, Van Hoesen GW, Damansio AR (1987) Alzheimer’s disease: glutamate depletion in the hippocampal perforant pathway zone. Ann Neurol 22: 37–40PubMedCrossRefGoogle Scholar
  9. Korey SR, Scheinberg L, Terry R, Stein A (1961) Studies in presenile dementia. Trans Am Neurol Assoc 86: 99–102PubMedGoogle Scholar
  10. Lowe SL, Francis PT, Procter AW, Palmer AM, Davison AN, Bowen DM (1988) Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer’s disease. Brain 111: 785–799PubMedCrossRefGoogle Scholar
  11. Lowe SL, Bowen DM (1990) Glutamic acid concentration in brains of patients with Alzheimer’s disease. Biochem Soc Trans (in press)Google Scholar
  12. McCabe BJ, Horn G (1988) Learning and memory: regional changes in N-methyl-D-aspartate receptors in the chick brain. Proc Natl Acad Sci (USA) 85: 2849–2855CrossRefGoogle Scholar
  13. Mohr E, Bruno G, Foster N, Gillespie M, Cox C, Hare TA, Tamminga C, Fedio P, Chase TN (1986) GABA-agonist therapy for Alzheimer’s disease. Clin Neuropharmacol 9: 257–263PubMedCrossRefGoogle Scholar
  14. Najlerahim A, Bowen DM (1988) Regional weight loss of the cerebral cortex and some subcortical nuclei in senile dementia of the Alzheimer type. Acta Neuropathol (Berl) 75: 509–512CrossRefGoogle Scholar
  15. Neary D, Snowden JS, Mann DMA, Northern B, Bowen DM, Sims NR, Yates PO, Davison AN (1986a) Alzheimer’s disease: a correlative study. J Neurol Neurosurg Psychiatry 49: 229–237PubMedCrossRefGoogle Scholar
  16. Perry TL, Young VW, Bergeron C, Hansen S, Jones K (1987) Amino acids, glutathione and glutathione transferase activity in the brains of patients with Alzheimer’s disease. Ann Neurol 21: 331–336PubMedCrossRefGoogle Scholar
  17. Procter AW, Palmer AM, Francis PT, Lowe SL, Neary D, Murphy E, Doshi R, Bowen DM (1988) Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer’s disease. J Neurochem 50: 790–802PubMedCrossRefGoogle Scholar
  18. Procter AW, Wong EHF, Stratmann GC, Lowe SL, Bowen DM (1989a) Reduced glycine stimulation of [3H]MK801 binding in Alzheimer’s disease. J Neurochem 53: 698–704PubMedCrossRefGoogle Scholar
  19. Procter AW, Stirling JM, Stratmann GC, Cross AJ, Bowen DM (1989b) Loss of glycine-dependent radioligand binding to the N-methyl-D-aspartate-phencyclidine receptor complex in patients with Alzheimer’s disease. Neurosci Lett 101: 62–66CrossRefGoogle Scholar
  20. Palmer AM, Hutson PH, Lowe SL, Bowen DM (1989) Extra-cellular concentrations of aspartate and glutamate in rat neostriatum following chemical stimulation of frontal cortex. Exp Brain Res 75: 659–663PubMedCrossRefGoogle Scholar
  21. Peinado JM, Mora F (1986) Glutamic acid as a putative transmitter of the interhemispheric corticocortical connections in the rat. J Neurochem 47: 1598–1603PubMedCrossRefGoogle Scholar
  22. Reinikainen KJ, Paljarvi L, Huuskonen M, Soininen H, Laakso M, Riekkinen PJ (1988) A postmortem study of noradrenergic, serotonergic and GABAergic neurones in Alzheimer’s disease. J Neurol Sci 84: 101–116PubMedCrossRefGoogle Scholar
  23. Steel JE, Palmer AM, Lowe SL, Bowen DM (1989a) The influence of tetrahydro-9-aminoacridine in excitatory amino acid neurotransmission in vivo and in vitro. Br J Pharmacol 96: 353Google Scholar
  24. Steel JE, Palmer HM, Stratmann GC, Bowen DM (1989b) The N-methyl-D-aspartate receptor complex in Alzheimer’s disease: reduced regulation by glycine but not zinc. Brain Res 500: 369–373CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1990

Authors and Affiliations

  • D. M. Bowen
    • 1
  • S. L. Lowe
    • 1
  1. 1.Institute of NeurologyDepartment of NeurochemistryLondonUK

Personalised recommendations